Literature DB >> 28934180

Notes from the Field: Travel-Associated Melioidosis and Resulting Laboratory Exposures - United States, 2016.

Patrick K Mitchell, Colin Campbell, Martha P Montgomery, Julie Paoline, Christopher Wilbur, Leah Posivak-Khouly, Kristin Garafalo, Mindy Elrod, Lindy Liu, Andre Weltman.   

Abstract

In mid-July 2016, a Pennsylvania resident aged 15 years who had recently returned from Thailand was treated by a pediatrician for sore throat, fever, and bilateral thigh abscesses at the sites of mosquito bites (Figure). She had traveled to northeast Thailand with nine other teens as part of an 18-day service-oriented trip run by an Ohio-based youth tour company that arranges travel to Thailand for approximately 500 persons annually. This trip included construction and agricultural activities and recreational mud exposures. The patient subsequently developed right inguinal lymphadenopathy and worsening abscesses, which prompted specimen collection for culture on August 25. This specimen was sent to a commercial laboratory in New Jersey, which identified Burkholderia pseudomallei, the causative organism of melioidosis, on August 30. The patient did not experience pneumonia or bacteremia, and recovered fully after 2 weeks of intensive therapy with parenteral ceftazidime and a 6-month outpatient course of eradication therapy with doxycycline.

Entities:  

Mesh:

Year:  2017        PMID: 28934180      PMCID: PMC5657778          DOI: 10.15585/mmwr.mm6637a8

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


In mid-July 2016, a Pennsylvania resident aged 15 years who had recently returned from Thailand was treated by a pediatrician for sore throat, fever, and bilateral thigh abscesses at the sites of mosquito bites (Figure). She had traveled to northeast Thailand with nine other teens as part of an 18-day service-oriented trip run by an Ohio-based youth tour company that arranges travel to Thailand for approximately 500 persons annually. This trip included construction and agricultural activities and recreational mud exposures. The patient subsequently developed right inguinal lymphadenopathy and worsening abscesses, which prompted specimen collection for culture on August 25. This specimen was sent to a commercial laboratory in New Jersey, which identified Burkholderia pseudomallei, the causative organism of melioidosis, on August 30. The patient did not experience pneumonia or bacteremia, and recovered fully after 2 weeks of intensive therapy with parenteral ceftazidime and a 6-month outpatient course of eradication therapy with doxycycline.
FIGURE

Thigh abscesses at the sites of mosquito bites in a Pennsylvania resident aged 15 years who had recently returned from Thailand, July 2016

Photo/patient (used with permission, name withheld for confidentiality)

* Photo taken 7 weeks after onset.

Thigh abscesses at the sites of mosquito bites in a Pennsylvania resident aged 15 years who had recently returned from Thailand, July 2016 Photo/patient (used with permission, name withheld for confidentiality) * Photo taken 7 weeks after onset. Melioidosis has variable, nonspecific presentation, which can include cutaneous infection, pneumonia, bacteremia, septicemia, and other manifestations, after an incubation period of 1–21 days, although longer incubations of months or years have been reported (,). It is typically acquired from direct contact with soil or water contaminated with B. pseudomallei, which is highly endemic in northeast Thailand (). Interviews with a tour company official revealed communication gaps regarding destination-specific health risks. With input from the Ohio and Pennsylvania Departments of Health, the tour company distributed a letter to participants and staff members who were on the patient’s trip, alerting them to melioidosis symptoms and exposure possibilities. No other trip participants responded to the letter to report symptoms. The tour company was advised to include CDC Yellow Book () resources in its predeparture materials for clients. B. pseudomallei is not reportable in Pennsylvania, but is listed as a Tier 1 select agent, indicating its potential to pose a serious health threat (). Although rare, laboratory acquisition of melioidosis through unknowing exposure to B. pseudomallei has been documented (,). Exposures for employees of the New Jersey commercial laboratory were categorized and managed according to published guidelines (). Among 41 laboratory technologists assessed, serologic testing and symptom self-monitoring was recommended for two technologists who were exposed to aerosols while manipulating the culture outside of a biologic safety cabinet, and two who had predisposing medical conditions (diabetes [one] and long-term steroid use [one]) and were present in the laboratory during the aerosol-generating procedures. The two technologists handling the culture were also prescribed trimethoprim-sulfamethoxazole for antibiotic prophylaxis. One technologist developed fever, cough, and rash and was temporarily excluded from work. This was diagnosed as an adverse reaction to trimethoprim-sulfamethoxazole and resolved after switching to doxycycline. No melioidosis cases were identified among exposed laboratory technologists. Because only zero to five cases of melioidosis are identified annually in the United States and the disease has nonspecific and possibly delayed symptoms, it might not initially be suspected as a diagnosis (,,). When patient travel history is compatible with B. pseudomallei exposure, clinicians should have a higher index of suspicion and share this suspicion with laboratory personnel to reduce exposure risk. Persons on service-oriented trips might be at higher risk for acquiring melioidosis than a typical traveler because of the potential for quasi-occupational exposures such as construction and farm work. Travelers should be advised to seek information about the particular health risks associated with their destinations and planned activities, and should share this information with health care providers if symptoms develop. Travel organizers should also be informed of the health risks related to the destinations they serve and types of trips they offer.
  4 in total

Review 1.  Melioidosis.

Authors:  W Joost Wiersinga; Bart J Currie; Sharon J Peacock
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

2.  Melioidosis and safety in the clinical laboratory.

Authors:  L R Ashdown
Journal:  J Hosp Infect       Date:  1992-08       Impact factor: 3.926

3.  Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.

Authors:  Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

Review 4.  Melioidosis in Travelers: Review of the Literature.

Authors:  Michael Dan
Journal:  J Travel Med       Date:  2015-09-10       Impact factor: 8.490

  4 in total
  3 in total

1.  Misidentification of Risk Group 3/Security Sensitive Biological Agents by MALDI-TOF MS in Canada: November 2015-October 2017.

Authors:  D Pomerleau-Normandin; M Heisz; M Su
Journal:  Can Commun Dis Rep       Date:  2018-05-03

2.  Low risk of acquiring melioidosis from the environment in the continental United States.

Authors:  Carina M Hall; Daniel Romero-Alvarez; Madison Martz; Ella Santana-Propper; Lora Versluis; Laura Jiménez; Abdelghafar Alkishe; Joseph D Busch; Trevor Maness; Jonathan Stewart; Tom Sidwa; Jay E Gee; Mindy G Elrod; Zachary Weiner; Alex R Hoffmaster; Jason W Sahl; Johanna S Salzer; A Townsend Peterson; Amanda Kieffer; David M Wagner
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

3.  Public health response to an imported case of canine melioidosis.

Authors:  C W Ryan; K Bishop; D D Blaney; S J Britton; F Cantone; C Egan; M G Elrod; C W Frye; A M Maxted; G Perkins
Journal:  Zoonoses Public Health       Date:  2018-02-16       Impact factor: 2.954

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.